Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Opinion|Videos|November 15, 2024
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations
Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.
Advertisement
- All: Please discuss the recent data on PFS and DOR for BRAF-MEK inhibitors combinations.
- Encorafenib + binimetinib (
Riely GJ, et al. J Clin Oncol. 2023 ) - Dabrafenib + trametinib (
Planchard D, et al. J Thorac Oncol. 2022 )
- Encorafenib + binimetinib (
- Have any new safety signals emerged from long-term follow-up?
- Encorafenib + binimetinib (
Smit E, et al. 2024.WCLC. MA06.13 - Encorafenib + binimetinib (
Riely G, et al. 2024.ESMO.LBA56 )- Impression of overall survival data
- Impact on clinical practice
- Difference in responses in first line vs second line
- Encorafenib + binimetinib (
- How do you choose between different BRAF-MEK inhibitor
- Based on the recent data presented at ESMO, how do you approach dose modifications?
- First-line immunotherapy vs BRAF and MEK inhibitors (
Di Federico A, et al. 2024. ESMO. Abstract 1299p ) - Treatment sequences in BRAF-V600 mutant (
Wiesweg M, et al. 2024. ESMO Abstract 1300p
Advertisement
Related to this article
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
3
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5